gmp
gmp

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ozanimod Hydrochloride

            Therapeutic Area: Neurology Product Name: Zeposia

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 07, 2020

            Details:

            ZEPOSIA® (0.92 mg) demonstrated a relative reduction in ARR versus AVONEX® of 48 per cent through one year in the SUNBEAM study and 38 per cent at two years in the RADIANCE study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fenfluramine Hydrochloride

            Therapeutic Area: Neurology Product Name: Fintepla

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $222.7 million Upfront Cash: Undisclosed

            Deal Type: Financing October 05, 2020

            Details:

            Zogenix intends to use the net proceeds from the offering to fund development and commercialization of Fintepla in Dravet syndrome, Lennox-Gastaut syndrome, and other potential indications, to fund the development of MT1621 in TK2 deficiency.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bupivacaine,Meloxicam

            Therapeutic Area: Neurology Product Name: Zynrelef

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 28, 2020

            Details:

            Zynrelef is a non-opioid, dual-acting analgesic, utilizing a fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fenfluramine Hydrochloride

            Therapeutic Area: Neurology Product Name: Fintepla

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $200.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering September 23, 2020

            Details:

            Zogenix intends to use the net proceeds from the offering to fund development and commercialization of Fintepla in Dravet syndrome, Lennox-Gastaut syndrome, to fund the development of MT1621 in TK2 deficiency and other general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Diazepam

            Therapeutic Area: Neurology Product Name: Valtoco

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 23, 2020

            Details:

            Upon completion of the clinical study, Neurelis plans to submit a supplemental NDA (sNDA) with the FDA to expand VALTOCO's label to include patients aged 2 and older. Chambliss said the company plans to file the sNDA in 2021.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sufentanil Citrate

            Therapeutic Area: Neurology Product Name: Dsuvia

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: U.S. Army

            Deal Size: $3.6 million Upfront Cash: Undisclosed

            Deal Type: Agreement September 22, 2020

            Details:

            AcelRx has been awarded the contract by the U.S. Army for the purchase of DSUVIA to support a study to aid the development of clinical practice guidelines. DSUVIA was designed to provide rapid analgesia via a non-invasive route and to eliminate IV associated dosing errors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bupivacaine

            Therapeutic Area: Neurology Product Name: Exparel

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 18, 2020

            Details:

            The CHMP positive opinion was based on the results of four pivotal Phase 3 studies that demonstrated improvements in pain reduction and opioid use.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lasmiditan

            Therapeutic Area: Neurology Product Name: Reyvow

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 11, 2020

            Details:

            Adults who took REYVOW C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 4.6 times greater odds, respectively, of achieving pain freedom at 2 hours compared to those taking placebo, according to results from the recently completed Phase 3 study CENTURION.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Opicapone

            Therapeutic Area: Neurology Product Name: Ongentys

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 11, 2020

            Details:

            Data demonstrated that newly approved Ongentys significantly reduced "off" time as an add-on therapy in patients with Parkinson's Disease taking Levodopa/Carbidopa only in a pooled Post-Hoc, sub-group analysis of Phase III studies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fenfluramine Hydrochloride

            Therapeutic Area: Neurology Product Name: Fintepla

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 10, 2020

            Details:

            FINTEPLA at 0.7 mg/kg/day achieved a 64.8% greater reduction in mean monthly convulsive seizures compared to placebo and FINTEPLA at a lower dose of 0.2 mg/kg/day achieved a 49.9% greater reduction in mean monthly convulsive seizures compared to placebo.

            PharmaCompass